BioSpace News Archive

MedX Health Corp. is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed amendment to the terms of the currently outstanding Convertible Loan Notes.

HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China.

BioArctic AB’s partner Eisai announced that LEQEMBI will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance drug price list.

The global gene synthesis market size is estimated to garner around USD 17.99 billion by 2032 and is expanding at a healthy CAGR of 23.97% from 2023 to 2032.

The global cell transfection market is expected to expand at a remarkable CAGR during the forecast period from 2023 to 2032.

Patients with newly diagnosed multiple myeloma (MM) who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) showed significantly higher rates of survival without disease progression compared with those who received standard care alone in a phase III trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) announces the completion of a Human Factors Study, whose objective was to assess the technology component developed to facilitate patient’s access to its erectile dysfunction drug, STENDRA® (avanafil), associated with the Company’s intended FDA application for prescription to OTC switch.

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.

The global cancer immunotherapy drug discovery outsourcing market size was exhibited at USD 2.11 billion in 2022 and is projected to hit around USD 5.87 billion by 2032, growing at a CAGR of 10.8% during the forecast period 2023 to 2032.

Cyclacel Pharmaceuticals, Inc. announced that it will implement a 1-for-15 Reverse Stock Split of its common stock, effective at 5:00 p.m. Eastern Time on Friday, December 15, 2023.